+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07625527

Randomized Study Comparing Active Surveillance to Continued Systemic Immunotherapy After Tumor-Free Status in Extensive Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Led by Tianjin Medical University Second Hospital · Updated on 2026-10-15

120

Participants Needed

4

Research Sites

165 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating if active surveillance is a feasible alternative to continued systemic immunotherapy after achieving tumor-free status in patients with extensive transurethrally unresectable very-high-risk non-muscle-invasive bladder cancer NMIBC. The study aims to address whether prolonged immunotherapy is necessary, considering the potential for increased toxicity, treatment burden, and cost. This phase 2 randomized trial focuses on patients who have undergone bladder-sparing treatment but still face uncertainty regarding optimal post-treatment management. Participants will first receive systemic PD-1PD-L1 inhibitor-based immunotherapy combined with transurethral resection of bladder tumor TURBT to achieve tumor-free status. After confirmation of tumor-free status through cystoscopy, biopsy, urine cytology, urinary tumor DNA testing, and imaging, participants will be randomized into different cohorts. Cohort A includes patients achieving early tumor-free status, randomized to either active surveillance with ongoing monitoring or continued immunotherapy for about one year. Cohort B includes patients who initially do not achieve tumor-free status but later do after additional TURBT and immunotherapy, then randomized similarly. During the study, participants will undergo regular assessments including cystoscopy, urine cytology, urinary tumor DNA testing, biopsies as needed, and imaging to monitor recurrence, progression, and bladder preservation. The primary outcome is bladder-intact event-free survival up to two years post-randomization. Secondary outcomes include recurrence-free survival, progression-free survival, overall survival, and treatment-related adverse events. The trial also explores urinary tumor DNA as a tool to guide treatment decisions and aims to balance effective disease control with minimizing treatment impact over a total participation period extending to study completion in 2032.

CONDITIONS

Brief Title

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Research Team

H

Hailong Hu, MD

Y

Yunkai Qie, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here